AbbVie Inc. (ABBV)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie Inc. NYSE: ABBV stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of $15.42 billion, beating expectations for $14.93 billion.
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie Stock Pops After Earnings Beat and Guidance Raised
Second quarter EPS came in at $2.97 on revenue of $15.4 billion, beating analysts expectations.
AbbVie in talks to acquire Gilgamesh Pharmaceuticals
Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, citing people familiar with the matter.
Sell AbbVie Stock Ahead of Its Upcoming Earnings?
AbbVie (NYSE:ABBV) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, understanding historical stock performance around earnings announcements can be a valuable tool.
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
